Alison Lannigan

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 120 citations

Breast Oncology, Medicine, Cancer Management +7

The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer

AM Al Murri, M Hilmy, Joshua A. Bell et al. · British Journal of Cancer · 2008 · 80 citations · Full text

Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer

A M Al Murri, Chris Wilson, Alison Lannigan et al. · British Journal of Cancer · 2007 · 74 citations · Full text

The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker

T Cooke, J. Reeves, Alison Lannigan et al. · European Journal of Cancer · 2001 · 66 citations

Tumor Biology, Prognostic Marker, Skin Development +8

Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast

Elizabeth Morrow, Alison Lannigan, Julie Doughty et al. · British journal of surgery · 2018 · 29 citations · Full text